Suiseng Coli /C Suspension for injection for pigs

Authorised

- Clostridium perfringens, type C, beta toxoid
- Clostridium novyi, type B, alpha toxoid
- Escherichia coli, fimbrial adhesin F6
- Escherichia coli, fimbrial adhesin F5
- Escherichia coli, fimbrial adhesin F4ac
- Escherichia coli, fimbrial adhesin F4ab
- Escherichia coli, LT toxoid

Product identification

Medicine name:
Suiseng Coli /C Suspension for injection for pigs

Active substance:
Clostridium perfringens, type C, beta toxoid

Clostridium novyi, type B, alpha toxoid

Escherichia coli, fimbrial adhesin F6

Escherichia coli, fimbrial adhesin F5

Escherichia coli, fimbrial adhesin F4ac

Escherichia coli, fimbrial adhesin F4ab

Escherichia coli, LT toxoid

Target species:
Pig

Route of administration:
Intramuscular use

Product details

Active substance and strength:
Clostridium perfringens, type C, beta toxoid
1.05 relative potency / 1.00 Dose

Clostridium novyi, type B, alpha toxoid
1.23 relative potency / 1.00 Dose

Escherichia coli, fimbrial adhesin F6
80.00 percent / 1.00 Dose

Escherichia coli, fimbrial adhesin F5
79.00 percent / 1.00 Dose

Escherichia coli, fimbrial adhesin F4ac
78.00 percent / 1.00 Dose

Escherichia coli, fimbrial adhesin F4ab
65.00 percent / 1.00 Dose

Escherichia coli, LT toxoid
55.00 percent / 1.00 Dose

Pharmaceutical form:
Suspension for injection

Withdrawal period by route of administration:
Intramuscular use:

- **Pig**
  - Meat and offal. 0 day

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QI09AB08

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

Authorisation status:
Valid

Authorised in:
Sweden

Package description:
20 ml Type-I colourless glass vials, closed with type I rubber stoppers and aluminium caps. Cardboard box with 1 glass vial of 10 doses (20 ml).
50 ml Type-I colourless glass vials, closed with type I rubber stoppers and aluminium caps. Cardboard box with 1 glass vial of 25 doses (50 ml).
100 ml Type-I colourless glass vials, closed with type I rubber stoppers and aluminium caps. Cardboard box with 1 glass vial of 50 doses (100 ml).
100 ml Type-I colourless glass vials, closed with type I rubber stoppers and aluminium caps. Cardboard box with 1 glass vial of 50 doses (100 ml).
100 ml PET plastic vials, closed with type I rubber stoppers and aluminium caps. Cardboard box with 1 PET vial of 50 doses (100 ml).
50 ml PET plastic vials, closed with type I rubber stoppers and aluminium caps. Cardboard box with 1 PET vial of 25 doses (50 ml).
20 ml PET plastic vials, closed with type I rubber stoppers and aluminium caps. Cardboard box with 1 PET vial of 10 doses (20 ml).

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Full application (Article 12(3) of Directive No 2001/82/EC)

Marketing authorisation holder:
Laboratorios Hipra S.A.

Marketing authorisation date:
27/04/2020

Manufacturing sites for batch release:
Laboratorios Hipra S.A.

Responsible authority:
Swedish Medical Products Agency

Authorisation number:
60038

Date of authorisation status change:
27/04/2020

Reference member state:
Ireland

Procedure number:
IE/V/0648/001

Concerned member states:
Austria Belgium Bulgaria Croatia Cyprus Czechia Denmark Estonia Finland France Germany Greece Hungary Iceland Italy Latvia Liechtenstein Lithuania Luxembourg Malta Netherlands Norway Poland Portugal Romania Slovakia Slovenia Spain Sweden United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics

English (PDF)
Published on: 20/04/2025
Download

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.

Combined File of all Documents